Investigational medication
Pharmaceutical compound
Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.[1][2]
References
- ^ Gerds AT, Bartalucci N, Assad A, Yacoub A (August 2022). "Targeting the PI3K pathway in myeloproliferative neoplasms". Expert Review of Anticancer Therapy. 22 (8): 835–843. doi:10.1080/14737140.2022.2093192. hdl:2158/1351132. PMID 35763287.
- ^ "Parsaclisib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG.